The first and the second types of diabetes mellitus, autoimmune and non-autoimmune thyroiditis differential diagnosis possibility using the calculated index based on plasma butyrylcholinesterase isoforms activity

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: The possibility of using a diagnostic index based on the use of blood plasma objective indicators to differentiate the diagnosis of type 1 and type 2 diabetes mellitus, autoimmune and non-autoimmune thyroiditis is an urgent task for timely decision-making on the use of a particular type of therapy, taking into account the etiology of a particular pathology. Changing the ratio of blood plasma butyrylcholinesterase isoforms activity makes it possible to identify increased excitability, to separate them among themselves depending on the genesis, and during treatment, to assess the activity of diseases and the effectiveness of therapeutic measures.

AIM: To develop a calculated diagnostic index for the differential diagnosis of diabetes and thyroiditis autoimmune type from symptomatically similar non-autoimmune pathologies, using the ratio of the plasma pseudocholinesterase isoforms activities.

MATERIALS AND METHODS: The study involved 188 people: 45 patients diagnosed with type 1 diabetes; 60 patients diagnosed with type 2 diabetes; 25 patients diagnosed with autoimmune thyroiditis; 25 patients with non-autoimmune thyroiditis; the control group consisted of 33 healthy volunteers. The groups were aligned by gender and age. Patients of all groups were examined by an endocrinologist and a therapeutist. The diagnoses were made in accordance with the Clinical Guidelines of the Russian Endocrinologists Association for the Diagnosis and Treatment of Autoimmune Thyroiditis in Adults, as well as the Clinical Guidelines “Type 1 Diabetes Mellitus in Adults”. In the blood plasma of all patients’ groups, the activity of pseudocholinesterase (butyrylcholinesterase) forms was determined by analysis using a modification of the Ellman’s method in combination with inhibitory analysis. The index was calculated based on the ratio of the studied enzyme typical and atypical forms activities. Based on the results of data analysis for all examined groups, diagnostic intervals were determined that are characteristic for each diagnosis, as well as for conditionally healthy people. Comparison of the patients distribution by categories of diagnosis was carried out using the Χ-square test with Yates correction in the SPSS 22 statistical software package.

RESULTS: The results of the blood plasma analysis determined that in the diagnoses of autoimmune thyroiditis and type 1 diabetes mellitus, there was an increase in the activity of increased activity of the butyrylcholinesterase isoform, while the activity of the atypical form remains more stable. The ratio of these forms was taken as the basis for the development of the calculated diagnostic index. Diagnostic index for the control group in the range of 1–2; for patients with non-autoimmune thyroiditis — 2,1–2,9; autoimmune thyroiditis — 3–3,5; type 1 diabetes mellitus — 3,6–5; type 2 diabetes — 0–1. Statistical analysis of the data showed that the diagnosis based on the index obtained in this way does not inferior to the diagnostic scales in terms of sensitivity and specificity. The findings are consistent with the evolution of data supporting each diagnosis.

CONCLUSIONS: The calculated index on the basis of butyrylcholinesterase activity is a promising, minimally invasive, fast and budgetary method, revealing a pronounced severity of occurrence in terms of symptoms, but different in etiology, type 1 diabetes mellitus and type 2 diabetes mellitus, autoimmune thyroiditis and thyroiditis of a non-autoimmune nature, which is of critical importance when choosing a therapeutic strategy and improving the quality of life of patients.

Full Text

Restricted Access

About the authors

Daria I. Kozlova

Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences

Author for correspondence.
Email: di.kozlova.official@gmail.com
ORCID iD: 0000-0003-1767-2754
SPIN-code: 2041-5544
Scopus Author ID: 56998634500
ResearcherId: Q-1916-2017

Cand. Sci. (Biol.), Senior Research Associate of the Laboratory of the Comparative Physiology and Pathology of the CNS

Russian Federation, Saint Petersburg

Vitaliy V. Khizha

Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences

Email: khizhaspb@gmail.com
ORCID iD: 0000-0003-4967-472X

Junior Research Associate of the Laboratory of the Comparative Physiology and Pathology of the CNS

Russian Federation, Saint Petersburg

Lyudmila V. Anosova

St.-Petersburg Scientific Research Institute of Ear, Nose, Throat and Speech

Email: anosova.ludmila@yandex.ru
ORCID iD: 0000-0002-3796-7616

Neurologist

Russian Federation, Saint Petersburg

Anastasia A. Korolkova

Pitirim Sorokin Syktyvkar State University

Email: ana9099588@yandex.ru
ORCID iD: 0000-0002-2159-1685

Senior Lecturer of the Department of the Therapy

Russian Federation, Syktyvkar

Svetlana S. Benevolenskaya

Almazov National Medical Research Centre

Email: stsebe@mail.ru
ORCID iD: 0000-0002-9817-1750
SPIN-code: 5521-3197

Rheumatologist of the Consultative and Diagnostic Department

Russian Federation, Saint Petersburg

Dmitrii S. Vasilev

Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences

Email: dvasilyev@bk.ru
ORCID iD: 0000-0002-0601-2358
SPIN-code: 3752-5516
Scopus Author ID: 42162286800
ResearcherId: J-8198-2018

Cand. Sci. (Biol.), Head of the Laboratory of the Comparative Physiology and Pathology of the CNS

Russian Federation, Saint Petersburg

Arseny V. Rybakov

Peter the Great St. Petersburg Polytechnic University

Email: aribakoff@gmail.com
ORCID iD: 0000-0001-8867-0161
SPIN-code: 9920-9315

Student

Russian Federation, Saint Petersburg

Karina A. Yureva

Saint-Petersburg State University

Email: st068449@student.spbu.ru
ORCID iD: 0000-0002-5225-3726

Student

Russian Federation, Saint Petersburg

Maria E. Shevaldina

Peter the Great St. Petersburg Polytechnic University

Email: mashasheval@gmail.com
ORCID iD: 0000-0002-9388-9886

Student

Russian Federation, Saint Petersburg

Marina F. Ballyzek

St. Petersburg Clinical Hospital of the Russian Academy of Sciences

Email: marina.ballyzek@mail.ru
ORCID iD: 0000-0003-3223-0241
SPIN-code: 2588-3944
Scopus Author ID: 55941807600

MD, Dr. Sci. (Med.), Cardiologist, Professor, Deputy Chief Physician for a Medical Part, Head of Cardiological Department

Russian Federation, Saint Petersburg

References

  1. Dedov II, Shestakova MV, Vikulova OK, et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204–221. (In Russ.) doi: 10.14341/DM12759
  2. Alessandri C, Conti F, Conigliaro P, et al. Seronegative autoimmune diseases. Ann NY Acad Sci. 2009;1173(1):52–59. doi: 10.1111/j.1749-6632.2009.04806.x
  3. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405(6785):458–462. doi: 10.1038/35013070
  4. Chasset F, Richez C, Martin T, et al. Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers). Joint Bone Spine. 2019;86(2):165–171. doi: 10.1016/j.jbspin.2018.10.007
  5. Marks M, Marks JL. Viral arthritis. Clin Med (Lond). 2016;16(2):129–134. doi: 10.7861/clinmedicine.16-2-129
  6. Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther. 2015;148:34–46. doi: 10.1016/j.pharmthera.2014.11.011
  7. Masson P., Lockridge O. Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior. Arch Biochem Biophys. 2010. Vol. 494, No. 2. P. 107–120. doi: 10.1016/j.abb.2009.12.005
  8. Dedov II, Melnichenko GA, Gerasimov GA, et al. Clinical recommendations of the Russian Association of Endocrinologists for the diagnosis and treatment of autoimmune thyroiditis in adults. Problems of Endocrinology. 2003;49(6):50. (In Russ.) doi: 10.14341/probl11777
  9. Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes mellitus type 1 in adults. Diabetes mellitus. 2020;23(1S):42–114. (In Russ.) doi: 10.14341/DM12505
  10. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7(2):88–95. doi: 10.1016/0006-2952(61)90145-9
  11. Patent RUS No. 2018000042/04.03.2018. Vasilev DS, Kozlova DI, Popov AV. Method for differential diagnosis of early or severe stage of rheumatoid arthritis with osteoarthritis. (In Russ.)
  12. Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol. 2008;154(8):1558–1571. doi: 10.1038/bjp.2008.185
  13. Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation Med Sci Monit. 2007;13(12):RA214–221. doi: 10.1016/S1665-2681(19)30940-8
  14. Grando SA, Kawashima K, Wessler I. Introduction: the non-neuronal cholinergic system in humans. Life Sci. 2003;72:2009–2012. doi: 10.1016/s0024-3205(03)00063-8
  15. Hofer S, Eisenbach C, Lukic IK, et al. Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med. 2008;36(2):404–408. doi: 10.1097/01.CCM.0B013E31816208B3
  16. Kawashima K, Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci. 2003;74(6):675–696. doi: 10.1016/j.lfs.2003.09.037
  17. Kozlova DI, Popov AV, Vasilyev DS, et al. Blood plasma pseudocholinesterase as a potential biomarker of autoimmune diseases. Russian Journal of Bioorganic Chemistry. 2018;44(2):173–177. doi: 10.1134/S106816201802005X
  18. Darvesh S, LeBlanc AM, Macdonald IR, et al. Butyrylcholinesterase activity in multiple sclerosis neuropathology. Chem Biol Interact. 2010;187(1–3):425–431. doi: 10.1016/j.cbi.2010.01.037

Supplementary files

Supplementary Files
Action
1. Fig. 1. Comparison of the insulin resistance index (HOMA-IR) (a) and the developed diagnostic index based on the activity of isoforms of butyrylcholinesterase (BChE) (b) diagrams. CG — control group; CD1 — type 1 diabetes mellitus; DM2 — type 2 diabetes mellitus. * statistically significant differences compared to CG and DM2 (p < 0.05); # statistically significant differences compared to CG and DM1 (p < 0.05)

Download (96KB)
2. Fig. 2. Comparison of diagrams showing the amount of antibodies to thyroglobulin (ab-TG) (a) and thyroperoxidase (ab-TPO) (b), with a diagram of the indicators by index based on the butyrylcholinesterase (BChE) analysis distribution (c). CG — control group; AIT — autoimmune thyroiditis; NAIT — non-autoimmune thyroiditis. * statistically significant differences compared to CG and NAIT (p < 0.05); # statistically significant differences compared to CG and AIT (p < 0.05)

Download (132KB)

Copyright (c) 2022 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies